title: Human epidermal growth factor receptor 2-targeted therapies in breast cancer.
abstract: Human epidermal growth factor receptor 2 (HER2) was acknowledged as an important therapeutic target in breast cancer more than 25 years ago. Subsequently, significant basic science and translational discoveries have resulted in the approval of four HER2-targeted therapies over the past 15 years. This editorial discusses future challenges regarding selection and development of treatments for HER2-positive breast cancer, which can only be met by continuing to support research efforts into the basic mechanisms by which cancer cells escape targeted therapies. Identifying specific molecular mechanisms underlying the sensitivity or resistance to each HER2-targeted agent will ultimately allow individualized therapy for each patient.
authors.forename: Rita
authors.initials: R
authors.lastname: Nahta
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
references.citation: Cancer Res. 2005 Dec 1;65(23):11118-28
references.pmid: 16322262
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Nature. 2003 Feb 13;421(6924):756-60
references.pmid: 12610629
references.citation: Cancer Discov. 2013 Feb;3(2):224-37
references.pmid: 23220880
references.citation: Science. 2002 Aug 23;297(5585):1330-3
references.pmid: 12154198
references.citation: Cancer Cell. 2004 Apr;5(4):317-28
references.pmid: 15093539
references.citation: Lancet Oncol. 2012 Jan;13(1):25-32
references.pmid: 22153890
references.citation: Cancer Res. 2009 Dec 15;69(24):9330-6
references.pmid: 19934333
references.citation: Cancer Res. 2004 Apr 1;64(7):2343-6
references.pmid: 15059883
references.citation: Cancer Res. 2011 Mar 1;71(5):1871-82
references.pmid: 21324925
references.citation: J Clin Oncol. 2012 May 10;30(14):1594-600
references.pmid: 22393084
references.citation: Cancer Cell. 2002 Aug;2(2):127-37
references.pmid: 12204533
references.citation: Clin Breast Cancer. 2010 Dec 1;10(6):489-91
references.pmid: 21147694
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6
references.pmid: 21385943